福司列弗多巴/卡比多巴改善睡眠与提高生活质量和运动症状相关。
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.
机构信息
Parkinson's Foundation International Centre of Excellence, King's College Hospital, London, UK.
King's College Institute of Psychiatry, Psychology & Neuroscience, London, UK.
出版信息
Mov Disord Clin Pract. 2024 Jul;11(7):861-866. doi: 10.1002/mdc3.14018. Epub 2024 Mar 11.
BACKGROUND
Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs.
OBJECTIVES
Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167).
METHODS
Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and "Off"/"On" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score.
RESULTS
Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved "Off" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, "Off" time, QoL, and m-EDL.
CONCLUSIONS
Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and "Off" time.
背景
Foslevodopa/foscarbidopa 是左旋多巴/卡比多巴前体药物的皮下输注。
目的
评估 foslevodopa/foscarbidopa （NCT03781167）的 3 期试验中期睡眠与疗效的相关性。
方法
使用 Pearson 相关系数评估基线和 26 周改善时睡眠（帕金森病睡眠量表-2 [PDSS-2]）与生活质量（帕金森病问卷-39 [PDQ-39]）、日常生活运动经验（m-EDL；运动障碍协会统一帕金森病量表第二部分）和“关”/“开”时间之间的相关性。回归分析根据基线 PDSS-2 评分进行了调整。
结果
基线睡眠与生活质量呈中度相关（r=0.44，P<0.001），与 m-EDL 呈弱相关（r=0.28；P<0.001）。睡眠改善与“关”时间（r=0.37；P<0.001）和生活质量（r=0.36；P<0.001）的改善呈弱相关。回归分析显示，睡眠、“关”时间、生活质量和 m-EDL 的改善均与显著的正相关。
结论
Foslevodopa/foscarbidopa 可改善睡眠，与生活质量和“关”时间的改善相关。
Zotero 插件